Literature DB >> 1374232

Critical evaluation of a theory of molecular recognition using human insulin-like-growth-factor-I fragment 21-40 and its complementary peptide.

J Beattie1, D J Flint.   

Abstract

Using solid-phase methods we have synthesized human insulin-like-growth-factor-I (IGF-I) fragment 21-40 (IGF-I 21-40) and the peptide derived from the 5'----3' translation of the complementary nucleic acid of this peptide, 'I-FGI 20-40' (the complementary peptide). According to a recently proposed theory of molecular recognition, these two peptides should bind specifically to each other. We have tested this theory by using both solid- and solution-phase direct-binding assays for this complementary-peptide pair. We have also investigated the ability of I-FGI 20-40 to interfere with native IGF-I binding during radioimmunoassay (r.i.a.), radio-receptor (r.r.a.) assay and ligand-blot analysis of IGF-binding proteins. We have obtained no evidence of any interaction between IGF-I 21-40 and I-FGI 20-40 in either solid- or solution-phase assays. In addition, I-FGI 20-40 does not interfere in the assays used to detect IGF-I binding antibodies (r.i.a.), receptors (r.r.a.) or binding proteins (ligand blots). Our data therefore question the universality of this particular theory of molecular recognition.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374232      PMCID: PMC1131059          DOI: 10.1042/bj2830473

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  An antibody to a peptide specified by an RNA that is complementary to gamma-endorphin mRNA recognizes an opiate receptor.

Authors:  D J Carr; K L Bost; J E Blalock
Journal:  J Neuroimmunol       Date:  1986-10       Impact factor: 3.478

Review 2.  Complementary peptides--theory and practice.

Authors:  J Beattie
Journal:  J Endocrinol       Date:  1990-08       Impact factor: 4.286

3.  Receptor-specific antibodies by immunization with "antisense" peptides?

Authors:  A N Eberle; R Drozdz; J B Baumann; J Girard
Journal:  Pept Res       Date:  1989 May-Jun

Review 4.  Ligand receptor characteristics of peptides encoded by complementary nucleic acids: implications for a molecular recognition code.

Authors:  J E Blalock; K L Bost
Journal:  Recent Prog Horm Res       Date:  1988

5.  The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor.

Authors:  M L Bayne; J Applebaum; D Underwood; G G Chicchi; B G Green; N S Hayes; M A Cascieri
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

6.  Recognition properties of antisense peptides to Arg8-vasopressin/bovine neurophysin II biosynthetic precursor sequences.

Authors:  G Fassina; M Zamai; M Brigham-Burke; I M Chaiken
Journal:  Biochemistry       Date:  1989-10-31       Impact factor: 3.162

7.  Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA.

Authors:  T S Elton; L D Dion; K L Bost; S Oparil; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  Antibodies to the binding site of the receptor for luteinizing hormone-releasing hormone (LHRH): generation with a synthetic decapeptide encoded by an RNA complementary to LHRH mRNA.

Authors:  J J Mulchahey; J D Neill; L D Dion; K L Bost; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  NMR study of the possible interaction in solution of angiotensin II with a peptide encoded by angiotensin II complementary RNA.

Authors:  H L Eaton; R E Austin; S W Fesik; S F Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Salicylate inhibits human placental sulphate transport in vitro.

Authors:  D B Shennan; T V Russell
Journal:  Biochem Pharmacol       Date:  1991-03-01       Impact factor: 5.858

View more
  1 in total

1.  Structural study of binding of flagellin by Toll-like receptor 5.

Authors:  Saul G Jacchieri; Ricardo Torquato; Ricardo R Brentani
Journal:  J Bacteriol       Date:  2003-07       Impact factor: 3.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.